Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro is the only brand name for tirzepatide licensed for weight management in the UK. There is no alternative UK brand — the two names, Mounjaro and tirzepatide, refer to exactly the same medicine made by Eli Lilly, and understanding that distinction matters before you go searching online. If you've seen other names attached to tirzepatide products (whether on social media, foreign pharmacy sites, or in news articles) this page explains what they are and why none of them are obtainable as licensed weight-loss treatment in Great Britain. These are prescription-only medicines; a GPhC-registered prescriber assesses clinical suitability before any treatment can begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Pharmaceutical companies routinely choose different brand names for the same medicine depending on which country they are selling it in. Eli Lilly selected Mounjaro as the brand name for tirzepatide across the UK and European markets. In the United States, the company markets the same active ingredient under two separate brand names: Mounjaro for diabetes and Zepbound for weight management.
That US split does not apply here. In the UK, a single MHRA-authorised licence covers tirzepatide under the Mounjaro name for both type 2 diabetes and weight management. So when UK readers encounter the Zepbound name (in a news story, a US health article, or an overseas online seller) they are reading about a product that has no legal standing as a UK medicine. It cannot be prescribed, dispensed, or legally imported for personal use as a licensed UK treatment.
You can read more about how the brand fits into the broader picture of tirzepatide and how it works, or explore the full Mounjaro overview if you want the clinical detail in one place.
No. If a UK pharmacy or online seller is offering tirzepatide under any name other than Mounjaro, that alone is a reason to pause. The MHRA's published guidance on GLP-1 medicines for weight loss makes clear that these are prescription-only products, the supply chain runs from the manufacturer through licenced wholesalers to GPhC-registered pharmacies, and the product arriving through that chain is always labelled as Mounjaro.
Counterfeit and illegally traded weight-loss medicines are a documented problem in the UK. When the MHRA raided an illicit manufacturing site in 2025, operatives found pens labelled to resemble authorised products but containing unverified substances. Unusual branding or unfamiliar product names from online sellers should be treated as a red flag, not a bargain. The MHRA Yellow Card scheme allows anyone to report a suspect seller, and it takes under two minutes.
If you are comparing treatment options more broadly, the weight-loss treatment overview sets out what is licensed in the UK for weight management and how the medicines differ.
This is a question our prescribers hear regularly, and it causes genuine confusion. The physical pen, the active ingredient, and the dose strengths are identical whether Mounjaro is prescribed for type 2 diabetes or for weight management. The difference lies in who is eligible for each indication and (critically for NHS patients) in whether treatment is funded.
A GP prescribing Mounjaro for a patient with type 2 diabetes is working within one licensed indication. A private prescriber approving it for a patient whose primary goal is weight management is working within the other. Both are legitimate; both require a proper clinical assessment. The medicine itself carries a Black Triangle (▼) symbol, meaning the MHRA continues to monitor it closely as a relatively new treatment, as the NHS tirzepatide page explains.
For cost context and what private weight-loss treatment typically involves, the guide to Mounjaro alongside other medications covers some of the clinical considerations, while additional benefits associated with Mounjaro summarises what the wider trial evidence has found beyond weight loss alone. If you would like to understand where tirzepatide sits in the prescription landscape, the tirzepatide brand guide goes into the MHRA authorisation in more detail. Pricing and what a private prescription includes is covered on the how to access Mounjaro page.
It is worth taking a moment to acknowledge that if you landed here after seeing Zepbound mentioned somewhere and wondering whether you could get it here, that is a completely understandable thing to search for. The short, honest answer: you cannot, and anything claiming otherwise is not following the rules that keep you safe. The good news is that the UK-licensed version, Mounjaro, is the same medicine and is available through regulated private clinics and pharmacies.
To check whether treatment might be suitable for you, start a free consultation with our prescribers and we will assess your circumstances properly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.